Aurobindo Pharma Q4 PAT falls marginally to Rs. 903 Cr

During the quarter, US formulations revenue increased by 13.5 per cent YoY to Rs. 4,072 crore

Apitoria Pharma gets Form 483 with 10 observations from USFDA

The observations are of procedural in nature and will be responded to within the stipulated time

Aurobindo Pharma’s subsidiary acquires Ace Laboratories, UK

Ace Lab conducts 170 batches of testing per month and has capacity to do more than 250 batches per month

Eugia SEZ’s injectable facility gets EIR from USFDA

The Unit has now received Establishment Inspection Report classifying the facility as Voluntary Action Indicated

Briefs: Eugia Pharma Specialities and Eugia SEZ

Eugia Pharma Specialities restarts production at terminally sterilized product lines

Aurobindo Pharma’s Eugia US Manufacturing to sell business assets to Empower Clinic Services for US$ 52 million

Eugia's East Windsor facility gets 10 observations from USFDA

The plant is yet to start commercial operations

Aurobindo's subsidiary Tergene Biotech receives SEC recommendation for pneumococcal 15 valent vaccine

The company continue to develop this program for the WHO markets, thereby providing coverage and protection for more infants globally in time to come

Aurobindo Pharma Q2 FY23 revenue down 3.4%

Formulation revenue decreased by 7.6% YoY to Rs. 4,770 crore whereas in Q2 FY23, API business posted a growth of 24.2% YoY with revenue of Rs. 969.4 crore

Aurobindo Pharma Foundation distributes 15 tri motor bikes to physically challenged persons at Jadcherla, Telangana

Aurobindo Pharma Foundation endeavours to make a positive contribution to the underprivileged ommunities by supporting a wide range of socio-economic, educational, and health initiatives.